Rumi Therapeutics signs option agreement for IND-ready RTX-7340 PDE2 inhibitor in Fragile X syndrome
Rumi Therapeutics secures an option to license RTX-7340 for Fragile X syndrome, with preclinical EEG findings supporting clinical development.
Pharma & Biotech